Loading stock data…
Schrödinger (SDGR)
$14.97-0.16 (-1.06%)
Market ClosedLast close Jul 24
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Africa, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Schrödinger, Inc. in the Healthcare sector is trading at $14.97 with a market capitalization of $1.1B. Wall Street consensus targets $20.57 (7 analysts), implying a +37.4% move over the next 12 months. The stock is currently 35% below its 52-week high of $23.02, remaining 2.5% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 25 is oversold, raising the odds of a near-term bounce; MACD remains below its signal line. The Whystock Score of 50/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +37.4% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Oversold momentum (RSI 25) — potential for technical mean-reversion
Quarterly Financials
| Metric (USD) | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|
| Total Revenue | $58.59M↓ | $87.23M↑ | $54.32M↓ | $54.76M↓ | $59.55M |
| Gross Profit | $29.55M↓ | $57.29M↑ | $28.04M↑ | $26.16M↓ | $31.12M |
| Operating Income | -$48.79M↓ | -$17.16M↑ | -$45.95M↑ | -$52.90M↓ | -$50.89M |
| Net Income | -$60.03M↓ | $32.51M↑ | -$32.80M↑ | -$43.17M↑ | -$59.81M |
Peer Comparison
JNJUNHPFE
Fundamentals
Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications in the United States, the Asia-Pacific, Europe, Middle East, Af...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.11B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-33.00%
Volume
Today's trading volume
956,430
Recent News
AMD Is Up 150% This Year But Here Are 5 Overlooked Stocks Betting on What Comes Next
The Pentagon just earmarked over $74 billion for drone dominance and counter drone technologies in the FY2027 budget request, and that is only one slice of the AI arms race AMD and NVIDIA are fighting over. While Wall Street obsesses over who wins the GPU throne, the real money in the next AI phase is ... AMD Is Up 150% This Year But Here Are 5 Overlooked Stocks Betting on What Comes Next
AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Artificial intelligence is reshaping nearly every industry, but some of its biggest opportunities are emerging far from Silicon Valley. Biotechnology has spent decades producing breakthrough medicines, yet drug development has remained painfully slow, often taking 10 to 15 years while roughly 90% of candidates never reach approval. AI is beginning to change that equation. By ... AI Is Transforming Drug Discovery. Here Is the Next Trillion-Dollar Biotech Opportunity
Strength Seen in Senseonics (SENS): Can Its 6.1% Jump Turn into More Strength?
Senseonics (SENS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Morgan Stanley Maintains an Equal Weight” rating on Schrödinger, Inc. (SDGR)
Schrödinger, Inc. (NASDAQ:SDGR) is among the Best Pharmaceutical Stocks. On May 14, Morgan Stanley lowered its price target on Schrödinger, Inc. (NASDAQ:SDGR) to $17 from $19. The firm maintained an “Equal Weight” rating on the shares. Separately, Schrödinger, Inc. (NASDAQ:SDGR) maintained full-year guidance for ACV of $218 million to $228 million. The corporation expects 10% to […]
What Does Schrodinger Inc (SDGR)’s 2026 Outlook Reveal?
Schrodinger Inc (NASDAQ:SDGR) is one of the best long-term stocks to invest in according to Bill & Melinda Gates Foundation Trust. The stock is backed by 31 hedge funds. Schrodinger shares are up around 13% over the past month, and analysts see more upside in the stock. On June 9, Schrodinger Inc (NASDAQ:SDGR) announced it […]